{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["Insomnia", "Lemborexant", "Ramelteon", "Suvorexant", "Switching", "Z-drugs"]], "CitationSubset": [], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "38460107", "DateCompleted": {"Year": "2024", "Month": "03", "Day": "25"}, "DateRevised": {"Year": "2024", "Month": "05", "Day": "18"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2024", "Month": "03", "Day": "09"}], "ELocationID": ["10.1007/s12325-024-02811-2"], "Journal": {"ISSN": "1865-8652", "JournalIssue": {"Volume": "41", "Issue": "4", "PubDate": {"Year": "2024", "Month": "Apr"}}, "Title": "Advances in therapy", "ISOAbbreviation": "Adv Ther"}, "ArticleTitle": "Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study.", "Pagination": {"StartPage": "1728", "EndPage": "1745", "MedlinePgn": "1728-1745"}, "Abstract": {"AbstractText": ["For patients with chronic insomnia, conventional therapy may not always provide satisfactory efficacy and safety. Thus, switching to an alternative therapeutic agent can be explored. However, there is a lack of prospective studies evaluating the effectiveness of such changes. This prospective, non-randomized, open-label, interventional, multicenter study assessed whether Japanese patients with chronic insomnia dissatisfied with treatment could transition directly to lemborexant (LEM) from four cohorts-non-benzodiazepine sedative-hypnotic (zolpidem, zopiclone, or eszopiclone) monotherapy, dual orexin receptor antagonist (suvorexant) monotherapy, suvorexant\u2009+\u2009benzodiazepine receptor agonists (BZRAs), and melatonin receptor agonist (ramelteon) combination. We evaluated whether transitioning to LEM improved patient satisfaction based on efficacy and safety.", "The primary endpoint was the proportion of successful transitions to LEM at 2\u00a0weeks (titration phase end), defined as the proportion of patients on LEM by the end of the 2-week titration phase who were willing to continue on LEM during the maintenance phase (Weeks 2-14). Patient satisfaction and safety (the incidence of treatment-emergent adverse events [TEAEs]) were assessed at 14\u00a0weeks (end of titration and maintenance phases).", "Among the 90 patients enrolled, 95.6% (95% confidence interval: 89.0-98.8%) successfully transitioned to LEM at 2\u00a0weeks. The proportions of patients who successfully continued on LEM were 97.8% and 82.2% at the end of the titration and maintenance phases (Weeks 2 and 14), respectively. The overall incidence of TEAEs was 47.8%; no serious TEAEs occurred. In all cohorts, the proportions of patients with positive responses were higher than the proportions with negative responses on the three scales of the Patient Global Impression-Insomnia version. During the maintenance phase, Insomnia Severity Index scores generally improved at Weeks 2, 6, and 14 of LEM transition.", "Direct transition to LEM may be a valid treatment option for patients with insomnia who are dissatisfied with current treatment.", "ClinicalTrials.gov identifier, NCT04742699."], "CopyrightInformation": "\u00a9 2024. The Author(s)."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Neuropsychiatry, Kurume University School of Medicine, 67 Asahi-machi, Kurume-shi, Fukuoka, Japan. ozone_motohiro@kurume-u.ac.jp."}], "LastName": "Ozone", "ForeName": "Motohiro", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Hirota Clinic, Fukuoka, Japan."}], "LastName": "Hirota", "ForeName": "Susumu", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "You Ariyoshi Sleep Clinic, Fukuoka, Japan."}], "LastName": "Ariyoshi", "ForeName": "Yu", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Sleep Support Clinic, Tokyo, Japan."}], "LastName": "Hayashida", "ForeName": "Kenichi", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Sleep Center, Kuwamizu Hospital, Kumamoto, Japan."}], "LastName": "Ikegami", "ForeName": "Azusa", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Neuropsychiatry, Kurume University School of Medicine, 67 Asahi-machi, Kurume-shi, Fukuoka, Japan."}], "LastName": "Habukawa", "ForeName": "Mitsunari", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Neuropsychiatry, Kurume University School of Medicine, 67 Asahi-machi, Kurume-shi, Fukuoka, Japan."}], "LastName": "Ohshima", "ForeName": "Hayato", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Sleep & Stress Clinic, Tokyo, Japan."}], "LastName": "Harada", "ForeName": "Daisuke", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Neuropsychiatry, Kurume University School of Medicine, 67 Asahi-machi, Kurume-shi, Fukuoka, Japan."}], "LastName": "Hiejima", "ForeName": "Hiroshi", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Kotorii Isahaya Hospital, Nagasaki, Japan."}], "LastName": "Kotorii", "ForeName": "Nozomu", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biostatistics Center, Kurume University, Fukuoka, Japan."}], "LastName": "Murotani", "ForeName": "Kenta", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Eisai Co., Ltd., Tokyo, Japan."}], "LastName": "Taninaga", "ForeName": "Takehiro", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Neuropsychiatry, Kurume University School of Medicine, 67 Asahi-machi, Kurume-shi, Fukuoka, Japan."}], "LastName": "Uchimura", "ForeName": "Naohisa", "Initials": "N"}], "DataBankList": [{"DataBankName": "ClinicalTrials.gov", "AccessionNumberList": ["NCT04742699"]}], "PublicationTypeList": ["Clinical Trial", "Multicenter Study", "Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Adv Ther", "NlmUniqueID": "8611864", "ISSNLinking": "0741-238X"}, "ChemicalList": [{"RegistryNumber": "0K5743G68X", "NameOfSubstance": "lemborexant"}, {"RegistryNumber": "081L192FO9", "NameOfSubstance": "suvorexant"}, {"RegistryNumber": "901AS54I69", "NameOfSubstance": "ramelteon"}, {"RegistryNumber": "0", "NameOfSubstance": "Triazoles"}, {"RegistryNumber": "0", "NameOfSubstance": "Azepines"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyridines"}, {"RegistryNumber": "0", "NameOfSubstance": "Indenes"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyrimidines"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Sleep Initiation and Maintenance Disorders"}, {"QualifierName": [], "DescriptorName": "Japan"}, {"QualifierName": [], "DescriptorName": "Prospective Studies"}, {"QualifierName": [], "DescriptorName": "Triazoles"}, {"QualifierName": [], "DescriptorName": "Azepines"}, {"QualifierName": [], "DescriptorName": "Pyridines"}, {"QualifierName": [], "DescriptorName": "Indenes"}, {"QualifierName": [], "DescriptorName": "Pyrimidines"}], "CoiStatement": "Motohiro Ozone received grants from Mitsubishi Tanabe Pharma Corporation, Tsumura Co., Ltd., Shionogi & Co., Ltd., Mochida Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., and Teijin Pharma Ltd.; and honoraria from Eisai Co., Ltd., Tsumura Co., Ltd., MSD Co., Ltd., Meiji Seika Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Nobelpharma Co., Ltd., Yoshitomi Pharmaceutical Industries, Ltd., and Mitsubishi Tanabe Pharma Corporation. Susumu Hirota received consulting fees from Viatris Inc.; honoraria from Eisai Co., Ltd., Meiji Seika Pharma Co., Ltd., Sumitomo Pharma Co., Ltd., and Takeda Pharmaceutical Company Ltd.; and is involved in clinical trials with Nippon Boehringer Ingelheim Co., Ltd., Shiongi & Co., Ltd., Sumitomo Pharma Co., Ltd., and Viatris Inc. Yu Ariyoshi received honoraria from Eisai Co., Ltd. and MSD Co., Ltd. Kenichi Hayashida received lecture fees from Eisai Co., Ltd. and MSD Co., Ltd. Azusa Ikegami received honoraria from Eisai Co., Ltd. Mitsunari Habukawa received honoraria from Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., MSD Co., Ltd., and Takeda Pharma Co., Ltd., Nozomu Kotorii received consulting fees from Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, MSD Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., and Janssen Pharmaceutical K.K. Takehiro Taninaga is an employee of Eisai Co., Ltd. Naohisa Uchimura received honoraria from Eisai Co., Ltd., Meiji Seika Pharma Co., Ltd., MSD Co., Ltd., Nobelpharma Co., Ltd., and Takeda Pharmaceutical Company Limited. The remaining authors have no conflicts of interest to declare."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Ohayon MM, Reynolds CF., 3rd Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD) Sleep Med. 2009;10:952\u2013960. doi: 10.1016/j.sleep.2009.07.008.", "ArticleIdList": ["10.1016/j.sleep.2009.07.008", "PMC3715324", "19748312"]}, {"Citation": "Itani O, Kaneita Y, Munezawa T, et al. Nationwide epidemiological study of insomnia in Japan. Sleep Med. 2016;25:130\u2013138. doi: 10.1016/j.sleep.2016.05.013.", "ArticleIdList": ["10.1016/j.sleep.2016.05.013", "27823706"]}, {"Citation": "Dopheide JA. Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy. Am J Manag Care. 2020;26:S76\u201384. doi: 10.37765/ajmc.2020.42769.", "ArticleIdList": ["10.37765/ajmc.2020.42769", "32282177"]}, {"Citation": "Sateia MJ. International Classification of Sleep Disorders\u2014third edition: highlights and modifications. Chest. 2014;146:1387\u20131394. doi: 10.1378/chest.14-0970.", "ArticleIdList": ["10.1378/chest.14-0970", "25367475"]}, {"Citation": "Sutton EL. Insomnia. Ann Intern Med. 2021;174:ITC33\u2013ITC48. doi: 10.7326/AITC202103160.", "ArticleIdList": ["10.7326/AITC202103160", "33683929"]}, {"Citation": "Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4:487\u2013504. doi: 10.5664/jcsm.27286.", "ArticleIdList": ["10.5664/jcsm.27286", "PMC2576317", "18853708"]}, {"Citation": "Kishi T, Nishida M, Koebis M, et al. Evidence-based insomnia treatment strategy using novel orexin antagonists: a review. Neuropsychopharmacol Rep. 2021;41:450\u2013458. doi: 10.1002/npr2.12205.", "ArticleIdList": ["10.1002/npr2.12205", "PMC8698673", "34553844"]}, {"Citation": "Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13:307\u2013349. doi: 10.5664/jcsm.6470.", "ArticleIdList": ["10.5664/jcsm.6470", "PMC5263087", "27998379"]}, {"Citation": "Glass J, Lanct\u00f4t KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331:1169. doi: 10.1136/bmj.38623.768588.47.", "ArticleIdList": ["10.1136/bmj.38623.768588.47", "PMC1285093", "16284208"]}, {"Citation": "Murakoshi A, Takaesu Y, Komada Y, Ishikawa J, Inoue Y. Prevalence and associated factors of hypnotics dependence among Japanese outpatients with psychiatric disorders. Psychiatry Res. 2015;230:958\u2013963. doi: 10.1016/j.psychres.2015.11.003.", "ArticleIdList": ["10.1016/j.psychres.2015.11.003", "26614012"]}, {"Citation": "Uemura SI, Imanishi A, Terui Y, et al. Residual effects of low dose of suvorexant, zolpidem, and ramelteon in healthy elderly subjects: a randomized double-blind study. Neuropsychopharmacol Rep. 2022;42:288\u2013298. doi: 10.1002/npr2.12262.", "ArticleIdList": ["10.1002/npr2.12262", "PMC9515713", "35748642"]}, {"Citation": "Takaesu Y, Sakurai H, Aoki Y, et al. Treatment strategy for insomnia disorder: Japanese expert consensus. Front Psychiatry. 2023;14:1168100. doi: 10.3389/fpsyt.2023.1168100.", "ArticleIdList": ["10.3389/fpsyt.2023.1168100", "PMC10203548", "37229388"]}, {"Citation": "Watson NF, Benca RM, Krystal AD, McCall WV, Neubauer DN. Alliance for Sleep Clinical Practice Guideline on switching or deprescribing hypnotic medications for insomnia. J Clin Med. 2023;12:2493. doi: 10.3390/jcm12072493.", "ArticleIdList": ["10.3390/jcm12072493", "PMC10095217", "37048577"]}, {"Citation": "Tannenbaum C, Farrell B, Shaw J, et al. An ecological approach to reducing potentially inappropriate medication use: Canadian Deprescribing Network. Can J Aging. 2017;36:97\u2013107. doi: 10.1017/S0714980816000702.", "ArticleIdList": ["10.1017/S0714980816000702", "28091333"]}, {"Citation": "American Geriatrics Society Beers Criteria Update Expert Panel American Geriatrics Society 2015 Updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227\u20132246. doi: 10.1111/jgs.13702.", "ArticleIdList": ["10.1111/jgs.13702", "26446832"]}, {"Citation": "Riemann D, Baglioni C, Bassetti C, et al. K. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26:675\u2013700. doi: 10.1111/jsr.12594.", "ArticleIdList": ["10.1111/jsr.12594", "28875581"]}, {"Citation": "ClinicalTrials.gov. Facilitation of zolpidem (\u226510 mg) discontinuation through use of ramelteon in subjects with chronic insomnia. Last updated 2010-07-20. Available at https://clinicaltrials.gov/study/NCT00492232. Accessed 06 July 2023."}, {"Citation": "Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opin Drug Metab Toxicol. 2020;16:1063\u20131078. doi: 10.1080/17425255.2020.1817380.", "ArticleIdList": ["10.1080/17425255.2020.1817380", "32901578"]}, {"Citation": "K\u00e4rpp\u00e4 M, Yardley J, Pinner K, et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep. 2020;43:zsaa123. doi: 10.1093/sleep/zsaa123.", "ArticleIdList": ["10.1093/sleep/zsaa123", "PMC7487867", "32585700"]}, {"Citation": "Rosenberg R, Murphy P, Zammit G, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open. 2019;2:e1918254. doi: 10.1001/jamanetworkopen.2019.18254.", "ArticleIdList": ["10.1001/jamanetworkopen.2019.18254", "PMC6991236", "31880796"]}, {"Citation": "Ahmad M, Kelly J, Montano B, et al. Transitioning insomnia patients from zolpidem to lemborexant: a multicenter, open-label study evaluating a next-dose transition approach to insomnia pharmacotherapy. Sleep Med X. 2024;7:10098. doi: 10.1016/j.sleepx.2023.100098.", "ArticleIdList": ["10.1016/j.sleepx.2023.100098", "PMC10835435", "38312371"]}, {"Citation": "Usui K, Fujii Y, Okada K, Suzuki E. Low-dose benzodiazepine receptor agonists may be completely replaced by lemborexant at about the same dose. Psychiatry Clin Neurosci Reports. 2022;1:e32. doi: 10.1002/pcn5.32.", "ArticleIdList": ["10.1002/pcn5.32"]}, {"Citation": "Kishi T, Sakuma K, Okuya M, Iwata N. Lemborexant for insomnia in adults with psychiatric disorders: a 1-week, open-label study. Psychiatry Clin Neurosci Reports. 2022;1:e23. doi: 10.1002/pcn5.23.", "ArticleIdList": ["10.1002/pcn5.23"]}, {"Citation": "American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 5. Washington: American Psychiatric Association; 2013."}, {"Citation": "Eisai Co., Ltd. Japanese package insert of DAYVIGO (lemborexant). 2022. Available at https://www.info.pmda.go.jp/go/pdf/170033_1190027F1022_1_04"}, {"Citation": "Eisai Inc. US prescribing information of DAYVIGO (lemborexant). 2023. Available at https://www.dayvigo.com/-/media/Files/DAYVIGO/PDF/prescribing-information.pdf"}, {"Citation": "MSD K.K. Japanese package insert of Belsomra (suvorexant). 2023. Available at https://pins.japic.or.jp/pdf/newPINS/00066563.pdf"}, {"Citation": "Okino K, Suzuki H, Tomioka H, et al. Efficacy and safety of lemborexant as an alternative drug for patients with insomnia taking gamma-aminobutyric acid-benzodiazepine receptor agonists or suvorexant. Hum Psychopharmacol. 2023;38:e2868. doi: 10.1002/hup.2868.", "ArticleIdList": ["10.1002/hup.2868", "36960814"]}, {"Citation": "De Crescenzo F, D\u2019Al\u00f2 GL, Ostinelli EG, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400:170\u2013184. doi: 10.1016/S0140-6736(22)00878-9.", "ArticleIdList": ["10.1016/S0140-6736(22)00878-9", "35843245"]}, {"Citation": "Greenblatt DJ, Legangneux E, Harmatz JS, et al. Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol. 2006;46:1469\u20131480. doi: 10.1177/0091270006293303.", "ArticleIdList": ["10.1177/0091270006293303", "17101746"]}, {"Citation": "Weinling E, McDougall S, Andre F, Bianchetti G, Dubruc C. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. Fundam Clin Pharmacol. 2006;20:397\u2013403. doi: 10.1111/j.1472-8206.2006.00415.x.", "ArticleIdList": ["10.1111/j.1472-8206.2006.00415.x", "16867025"]}, {"Citation": "Kishi T, Nomura I, Matsuda Y, et al. Lemborexant vs suvorexant for insomnia: a systematic review and network meta-analysis. J Psychiatr Res. 2020;128:68\u201374. doi: 10.1016/j.jpsychires.2020.05.025.", "ArticleIdList": ["10.1016/j.jpsychires.2020.05.025", "32531478"]}, {"Citation": "Kishi T, Sakuma K, Okuya M, et al. Suvorexant for insomnia in patients with psychiatric disorder: a 1-week, open-label study. Neuropsychopharmacol Rep. 2019;39:252\u2013255. doi: 10.1002/npr2.12069.", "ArticleIdList": ["10.1002/npr2.12069", "PMC7292311", "31283862"]}, {"Citation": "Hatano M, Kamei H, Inagaki R, et al. Assessment of switching to suvorexant versus the use of add-on suvorexant in combination with benzodiazepine receptor agonists in insomnia patients: a retrospective study. Clin Psychopharmacol Neurosci. 2018;16:184\u2013189. doi: 10.9758/cpn.2018.16.2.184.", "ArticleIdList": ["10.9758/cpn.2018.16.2.184", "PMC5953018", "29739132"]}, {"Citation": "Okino K, Suzuki H, Kondo S, et al. Effectiveness of change from suvorexant to lemborexant drug in the treatment of sleep disorders. Psychogeriatrics. 2022;22:595\u2013604. doi: 10.1111/psyg.12858.", "ArticleIdList": ["10.1111/psyg.12858", "35689366"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "8", "Day": "21"}, {"Year": "2024", "Month": "2", "Day": "2"}, {"Year": "2024", "Month": "3", "Day": "25", "Hour": "6", "Minute": "43"}, {"Year": "2024", "Month": "3", "Day": "9", "Hour": "20", "Minute": "42"}, {"Year": "2024", "Month": "3", "Day": "9", "Hour": "11", "Minute": "11"}, {"Year": "2024", "Month": "3", "Day": "9"}], "PublicationStatus": "ppublish", "ArticleIdList": ["38460107", "PMC10960898", "10.1007/s12325-024-02811-2", "10.1007/s12325-024-02811-2"]}}], "PubmedBookArticle": []}